Joseph Manni Sells 1,361 Shares of CeriBell (NASDAQ:CBLL) Stock

CeriBell, Inc. (NASDAQ:CBLL) CRO Joseph Manni sold 1,361 shares of the stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $24.02, for a total value of $32,691.22. Following the completion of the transaction, the executive directly owned 55,956 shares of the company’s stock, valued at $1,344,063.12. This represents a 2.37% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

CeriBell Stock Up 0.0%

Shares of NASDAQ CBLL traded up $0.01 during mid-day trading on Tuesday, hitting $23.95. 243,381 shares of the stock traded hands, compared to its average volume of 457,237. The company has a market cap of $919.20 million, a price-to-earnings ratio of -13.61 and a beta of 0.81. The stock has a fifty day moving average price of $19.77 and a 200-day moving average price of $19.27. CeriBell, Inc. has a 52 week low of $10.85 and a 52 week high of $25.33. The company has a debt-to-equity ratio of 0.16, a quick ratio of 8.79 and a current ratio of 9.18.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.04). The firm had revenue of $28.10 million during the quarter, compared to the consensus estimate of $27.28 million. CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%. Research analysts anticipate that CeriBell, Inc. will post -1.96 EPS for the current year.

Analyst Ratings Changes

CBLL has been the subject of a number of recent research reports. Barclays raised shares of CeriBell to a “neutral” rating in a research report on Tuesday, August 18th. Canaccord Genuity Group upped their price objective on shares of CeriBell from $25.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Weiss Ratings raised shares of CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 13th. Finally, BTIG Research lifted their target price on shares of CeriBell from $28.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday, August 18th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $22.40.

Hedge Funds Weigh In On CeriBell

Several institutional investors and hedge funds have recently modified their holdings of the stock. TimesSquare Capital Management LLC purchased a new position in shares of CeriBell in the 2nd quarter worth about $15,182,000. Royce & Associates LP purchased a new stake in CeriBell during the 4th quarter valued at about $11,695,000. KCM Capital Inc grew its position in CeriBell by 40.0% during the 1st quarter. KCM Capital Inc now owns 1,400,000 shares of the company’s stock valued at $25,662,000 after purchasing an additional 400,000 shares during the last quarter. Landscape Capital Management L.L.C. bought a new stake in CeriBell during the 2nd quarter valued at about $2,078,000. Finally, Kopp Family Office LLC purchased a new position in CeriBell in the second quarter worth about $672,000.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.